| 摘要: |
| 结核分枝杆菌感染引起的结核病是世界范围内发病率和死亡率较高的传染病之一。其主要通过呼吸道传播进而侵犯肺脏，肺结核又分为药物敏感肺结核与耐药肺结核，药物敏感肺结核至少要接受6个月的治疗，而耐药肺结核中的耐多药肺结核传统治疗疗程则更为漫长，所以肺结核的短程治疗一直是近年来研究的热点，其研究成果将促进结核病病例管理并在疾病控制方面做出重大改进，本文就目前肺结核的短程治疗进展进行综述。 |
| 关键词: 肺结核 短程治疗 耐多药肺结核 |
| DOI：10.12289/j.issn.2097-4345.23191 |
| 通信作者: |
| 投稿时间：2023-06-07 |
| 录用日期： |
| 基金项目:上海市感染性疾病（结核病）临床医学研究中心建设项目（19MC1910800）;上海市临床重点专科（shslczdzk03001） |
|
| Research progress of short-course treatment for pulmonary tuberculosis |
| DU Shanshan,SHA Wei |
| (Department of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China) |
| Abstract: |
| Tuberculosis(TB) is an infectious diseases with substantial morbidity and mortality worldwide. Drug-sensitive TB requires at least 6 months of anti-tuberculosis treatment, while the traditional course for multidrug-resistant tuberculosis(MDR-TB) is much longer. Therefore, to promote significant improvement in TB management and disease control, short-course TB treatment has become a research focus in recent years. This article reviews the current progress of short-course treatment of pulmonary tuberculosis. |
| Key words: tuberculosis short-course treatment multidrug-resistant tuberculosis |
